multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer
Objective The objective of this study was to evaluate the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy in patients with metastatic esophageal cancer. Methods Patients with untreated metastatic squamous cell esophageal cancer, which was histologically proven with at least...
Saved in:
Published in | Cancer chemotherapy and pharmacology Vol. 66; no. 1; pp. 31 - 36 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Berlin/Heidelberg
Berlin/Heidelberg : Springer-Verlag
01.05.2010
Springer-Verlag Springer Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objective The objective of this study was to evaluate the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy in patients with metastatic esophageal cancer. Methods Patients with untreated metastatic squamous cell esophageal cancer, which was histologically proven with at least one measurable lesion, were eligible for the study. Docetaxel 70 mg/m² and cisplatin 70 mg/m² were intravenously given on day 1 of 21 days schedule. Results From December 2004 to December 2007, total of 39 patients (M/F = 39/0) were enrolled. The median age was 65 years. Thirty-four patients were evaluable for response. There were 3 (7.7%) complete remission, 10 (25.6%) partial remission, 11 (28.2%) stable disease, and 10 (25.6%) progression disease. The objective tumor response rate was 33.3% in intention-to-treat (ITT). Median PFS was 5.0 months and median survival was 8.3 months. Median number of cycles administered was 3. The relative dose intensity of docetaxel and cisplatin was 92 and 91%, respectively. This treatment was comparatively tolerated with grade 3/4 neutropenia in 20.5%/10.3%, grade 3 infection in 2.6% of patients. Conclusion Docetaxel plus cisplatin combination chemotherapy showed promising antitumor activity with manageable toxicities in patients with metastatic squamous esophageal cancer. |
---|---|
AbstractList | Objective: The objective of this study was to evaluate the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy in patients with metastatic esophageal cancer. Methods: Patients with untreated metastatic squamous cell esophageal cancer, which was histologically proven with at least one measurable lesion, were eligible for the study. Docetaxel 70mg/m super(2) and cisplatin 70mg/m super(2) were intravenously given on day 1 of 21days schedule. Results: From December 2004 to December 2007, total of 39 patients (M/F=39/0) were enrolled. The median age was 65years. Thirty-four patients were evaluable for response. There were 3 (7.7%) complete remission, 10 (25.6%) partial remission, 11 (28.2%) stable disease, and 10 (25.6%) progression disease. The objective tumor response rate was 33.3% in intention-to-treat (ITT). Median PFS was 5.0months and median survival was 8.3months. Median number of cycles administered was 3. The relative dose intensity of docetaxel and cisplatin was 92 and 91%, respectively. This treatment was comparatively tolerated with grade 3/4 neutropenia in 20.5%/10.3%, grade 3 infection in 2.6% of patients. Conclusion: Docetaxel plus cisplatin combination chemotherapy showed promising antitumor activity with manageable toxicities in patients with metastatic squamous esophageal cancer. The objective of this study was to evaluate the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy in patients with metastatic esophageal cancer. Patients with untreated metastatic squamous cell esophageal cancer, which was histologically proven with at least one measurable lesion, were eligible for the study. Docetaxel 70 mg/m^sup 2^ and cisplatin 70 mg/m^sup 2^ were intravenously given on day 1 of 21 days schedule. From December 2004 to December 2007, total of 39 patients (M/F = 39/0) were enrolled. The median age was 65 years. Thirty-four patients were evaluable for response. There were 3 (7.7%) complete remission, 10 (25.6%) partial remission, 11 (28.2%) stable disease, and 10 (25.6%) progression disease. The objective tumor response rate was 33.3% in intention-to-treat (ITT). Median PFS was 5.0 months and median survival was 8.3 months. Median number of cycles administered was 3. The relative dose intensity of docetaxel and cisplatin was 92 and 91%, respectively. This treatment was comparatively tolerated with grade 3/4 neutropenia in 20.5%/10.3%, grade 3 infection in 2.6% of patients. Docetaxel plus cisplatin combination chemotherapy showed promising antitumor activity with manageable toxicities in patients with metastatic squamous esophageal cancer.[PUBLICATION ABSTRACT] The objective of this study was to evaluate the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy in patients with metastatic esophageal cancer. Patients with untreated metastatic squamous cell esophageal cancer, which was histologically proven with at least one measurable lesion, were eligible for the study. Docetaxel 70 mg/m(2) and cisplatin 70 mg/m(2) were intravenously given on day 1 of 21 days schedule. From December 2004 to December 2007, total of 39 patients (M/F = 39/0) were enrolled. The median age was 65 years. Thirty-four patients were evaluable for response. There were 3 (7.7%) complete remission, 10 (25.6%) partial remission, 11 (28.2%) stable disease, and 10 (25.6%) progression disease. The objective tumor response rate was 33.3% in intention-to-treat (ITT). Median PFS was 5.0 months and median survival was 8.3 months. Median number of cycles administered was 3. The relative dose intensity of docetaxel and cisplatin was 92 and 91%, respectively. This treatment was comparatively tolerated with grade 3/4 neutropenia in 20.5%/10.3%, grade 3 infection in 2.6% of patients. Docetaxel plus cisplatin combination chemotherapy showed promising antitumor activity with manageable toxicities in patients with metastatic squamous esophageal cancer. Objective The objective of this study was to evaluate the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy in patients with metastatic esophageal cancer. Methods Patients with untreated metastatic squamous cell esophageal cancer, which was histologically proven with at least one measurable lesion, were eligible for the study. Docetaxel 70 mg/m² and cisplatin 70 mg/m² were intravenously given on day 1 of 21 days schedule. Results From December 2004 to December 2007, total of 39 patients (M/F = 39/0) were enrolled. The median age was 65 years. Thirty-four patients were evaluable for response. There were 3 (7.7%) complete remission, 10 (25.6%) partial remission, 11 (28.2%) stable disease, and 10 (25.6%) progression disease. The objective tumor response rate was 33.3% in intention-to-treat (ITT). Median PFS was 5.0 months and median survival was 8.3 months. Median number of cycles administered was 3. The relative dose intensity of docetaxel and cisplatin was 92 and 91%, respectively. This treatment was comparatively tolerated with grade 3/4 neutropenia in 20.5%/10.3%, grade 3 infection in 2.6% of patients. Conclusion Docetaxel plus cisplatin combination chemotherapy showed promising antitumor activity with manageable toxicities in patients with metastatic squamous esophageal cancer. Objective The objective of this study was to evaluate the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy in patients with metastatic esophageal cancer. Methods Patients with untreated metastatic squamous cell esophageal cancer, which was histologically proven with at least one measurable lesion, were eligible for the study. Docetaxel 70 mg/m 2 and cisplatin 70 mg/m 2 were intravenously given on day 1 of 21 days schedule. Results From December 2004 to December 2007, total of 39 patients (M/F = 39/0) were enrolled. The median age was 65 years. Thirty-four patients were evaluable for response. There were 3 (7.7%) complete remission, 10 (25.6%) partial remission, 11 (28.2%) stable disease, and 10 (25.6%) progression disease. The objective tumor response rate was 33.3% in intention-to-treat (ITT). Median PFS was 5.0 months and median survival was 8.3 months. Median number of cycles administered was 3. The relative dose intensity of docetaxel and cisplatin was 92 and 91%, respectively. This treatment was comparatively tolerated with grade 3/4 neutropenia in 20.5%/10.3%, grade 3 infection in 2.6% of patients. Conclusion Docetaxel plus cisplatin combination chemotherapy showed promising antitumor activity with manageable toxicities in patients with metastatic squamous esophageal cancer. |
Author | Do, Young Rok Park, Keon Uk Ryoo, Hun Mo Kim, Min Kyung Baek, Jin Ho Song, Hong Suk Lee, Kyung Hee Kim, Jin Young Bae, Sung Hwa |
Author_xml | – sequence: 1 fullname: Kim, Jin Young – sequence: 2 fullname: Do, Young Rok – sequence: 3 fullname: Park, Keon Uk – sequence: 4 fullname: Kim, Min Kyung – sequence: 5 fullname: Lee, Kyung Hee – sequence: 6 fullname: Bae, Sung Hwa – sequence: 7 fullname: Ryoo, Hun Mo – sequence: 8 fullname: Baek, Jin Ho – sequence: 9 fullname: Song, Hong Suk |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22655808$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19763571$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kUuLFDEUhYOMOD2jP8CNBkFcld68qipLGXw0DLjQWYdU6lZ3DfWa3BTaP8F_bZpuHHDhKpD7nXMP91yxi2mekLGXAt4LgOoDAcgaCgBbCKGgKJ-wjdBKFlBrdcE2oLQuTAX6kl0R3QOAFko9Y5fCVqUyldiw3-M6pL4IOCWMfNl7Qr7dckpre-Bzx9s5YPK_cODLsBIPPS2DT_3EPfGuj5SKoZ-Qpz1Gvxx4Hix5nN2I_-zTno9ZTSl_BU4Pqx_nowkOA0ea87Yd-oEHPwWMz9nTzg-EL87vNbv7_OnHzdfi9tuX7c3H2yJoU6ZCNGVZ1RaC1m0D2KDVVtogW4MCA7Rl45W0HkLnlbG1bU2DTWcUeKOVqry6Zu9OvkucH1ak5MaejpH8hDmdq7Q21tRWZvLNP-T9vMYph3NS5NNKbSFD4gSFOBNF7NwS-9HHgxPgji25U0sut-SOLbkya16djddmxPZRca4lA2_PgKfghy7mC_X0l5OyNKaGOnPyxFEeTTuMjwn_t_31SdT52fldzMZ33yXkoaillTnCHzymtso |
CODEN | CCPHDZ |
CitedBy_id | crossref_primary_10_3892_mco_2013_79 crossref_primary_10_1186_1477_7819_10_173 crossref_primary_10_3390_cancers13194766 crossref_primary_10_6004_jnccn_2019_0033 crossref_primary_10_1186_s13014_020_01518_2 crossref_primary_10_1007_s00432_022_04066_2 crossref_primary_10_2217_fon_2020_1191 crossref_primary_10_1007_s00280_012_1962_3 crossref_primary_10_1002_mef2_56 crossref_primary_10_4166_kjg_2012_60_2_113 crossref_primary_10_1177_17588359221138377 crossref_primary_10_4161_cbt_22627 crossref_primary_10_7314_APJCP_2015_16_12_4993 crossref_primary_10_18632_oncotarget_13602 crossref_primary_10_1007_s12094_019_02151_6 crossref_primary_10_6004_jnccn_2022_0008 crossref_primary_10_1007_s00066_021_01894_y |
Cites_doi | 10.1385/IJGC:32:2-3:115 10.1093/jnci/92.3.205 10.1200/JCO.1991.9.11.2042 10.1023/A:1014476602804 10.1159/000089102 10.1016/S0959-8049(97)00088-9 10.1093/annonc/mdh231 10.1200/JCO.1998.16.5.1826 10.1038/sj.bjc.6602645 10.1038/sj.bjc.6600166 10.1200/JCO.1994.12.6.1238 10.1097/00001813-199801000-00001 10.1038/sj.bjc.6601168 10.1007/BF02993858 10.1093/jnci/86.14.1086 10.1016/0197-2456(89)90015-9 10.1038/bjc.1998.524 |
ContentType | Journal Article |
Copyright | Springer-Verlag 2009 2015 INIST-CNRS Springer-Verlag 2010 |
Copyright_xml | – notice: Springer-Verlag 2009 – notice: 2015 INIST-CNRS – notice: Springer-Verlag 2010 |
DBID | FBQ IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7TO 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. M0S M1P PQEST PQQKQ PQUKI PRINS 7U7 C1K |
DOI | 10.1007/s00280-009-1130-6 |
DatabaseName | AGRIS Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Proquest Health and Medical Complete ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central AUTh Library subscriptions: ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Toxicology Abstracts Environmental Sciences and Pollution Management |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Public Health Oncogenes and Growth Factors Abstracts ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) AIDS and Cancer Research Abstracts ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) Toxicology Abstracts Environmental Sciences and Pollution Management |
DatabaseTitleList | Toxicology Abstracts ProQuest Public Health MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: Proquest Health and Medical Complete url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database – sequence: 4 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1432-0843 |
EndPage | 36 |
ExternalDocumentID | 2010827901 10_1007_s00280_009_1130_6 19763571 22655808 US201301829276 |
Genre | Multicenter Study Clinical Trial, Phase II Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -53 -56 -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 1N0 1SB 2.D 203 28- 29B 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67Z 6NX 6PF 78A 7X7 88E 8AO 8C1 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJKR AAKSU AANXM AANZL AARHV AARTL AATNV AATVU AAUYE AAWCG AAWTL AAYFA AAYIU AAYQN AAYTO ABBBX ABBXA ABDZT ABECU ABFGW ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKAS ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABPTK ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACBMV ACBRV ACBXY ACBYP ACGFS ACHSB ACHVE ACHXU ACIGE ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACTTH ACUDM ACVWB ACWMK ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEEQQ AEFIE AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFAFS AFDYV AFEXP AFFNX AFJLC AFKRA AFLOW AFNRJ AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGKHE AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FBQ FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- MK0 N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SBL SCLPG SDE SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 Y6R YLTOR Z45 Z7U Z7V Z7X Z82 Z83 Z87 Z8O Z8P Z8V Z8W Z91 ZGI ZMTXR ZOVNA ~EX ~KM AAPBV H13 IQODW AACDK AAEOY AAJBT AASML AAYZH ABAKF ACAOD ACDTI ACZOJ AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU AJOOF ALIPV CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TO 7XB 8FK H94 K9. PQEST PQUKI PRINS 7U7 C1K |
ID | FETCH-LOGICAL-c456t-1b667890c44db0ebe94929c2d5e1ec0d6ba329a0cfa35989d5bebf530a54337a3 |
IEDL.DBID | BENPR |
ISSN | 0344-5704 |
IngestDate | Fri Aug 16 01:43:24 EDT 2024 Thu Oct 10 22:50:38 EDT 2024 Thu Sep 12 18:47:13 EDT 2024 Tue Oct 15 23:40:40 EDT 2024 Sun Oct 22 16:07:03 EDT 2023 Sat Dec 16 12:00:17 EST 2023 Wed Dec 27 19:12:04 EST 2023 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Combination chemotherapy Esophageal cancer Cisplatin Docetaxel Antineoplastic agent Esophageal disease Metastasis Esophagus cancer Taxane derivatives Phase II trial Advanced stage Antimitotic Platinum II Complexes Human Drug combination Squamous cell carcinoma Digestive system Patient Malignant tumor Esophagus First line treatment Alkylating agent Digestive diseases Combined treatment Cancer |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c456t-1b667890c44db0ebe94929c2d5e1ec0d6ba329a0cfa35989d5bebf530a54337a3 |
Notes | http://dx.doi.org/10.1007/s00280-009-1130-6 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
PMID | 19763571 |
PQID | 213442490 |
PQPubID | 48447 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_744595892 proquest_journals_213442490 crossref_primary_10_1007_s00280_009_1130_6 pubmed_primary_19763571 pascalfrancis_primary_22655808 springer_journals_10_1007_s00280_009_1130_6 fao_agris_US201301829276 |
PublicationCentury | 2000 |
PublicationDate | 2010-05-01 |
PublicationDateYYYYMMDD | 2010-05-01 |
PublicationDate_xml | – month: 05 year: 2010 text: 2010-05-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Berlin/Heidelberg |
PublicationPlace_xml | – name: Berlin/Heidelberg – name: Heidelberg – name: Germany |
PublicationTitle | Cancer chemotherapy and pharmacology |
PublicationTitleAbbrev | Cancer Chemother Pharmacol |
PublicationTitleAlternate | Cancer Chemother Pharmacol |
PublicationYear | 2010 |
Publisher | Berlin/Heidelberg : Springer-Verlag Springer-Verlag Springer Springer Nature B.V |
Publisher_xml | – name: Berlin/Heidelberg : Springer-Verlag – name: Springer-Verlag – name: Springer – name: Springer Nature B.V |
References | JatoiATironaMTChaSSA phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardiaInt J Gastrointest Cancer20023211512310.1385/IJGC:32:2-3:1151:CAS:528:DC%2BD3sXlvV2rsrw%3D12794247 SparreboomAvan TellingenONooijenWJPreclinical pharmacokinetics of paclitaxel and docetaxelAnticancer Drugs1998911710.1097/00001813-199801000-000011:CAS:528:DyaK1cXotVOrug%3D%3D9491787 LaackEAndritzkyBDurkHDocetaxel and cisplatin as first-line treatment for patients with metastatic esophageal cancer: a pilot studyOnkologie20052864765010.1159/0000891021:CAS:528:DC%2BD28Xhsl2qug%3D%3D16330888 AjaniJAIlsonDHDaughertyKActivity in patients with squamous cell carcinoma and adenocarcinoma of the esophagusJ Natl Cancer Inst1994861086109110.1093/jnci/86.14.10861:STN:280:DyaK2c3ptlensg%3D%3D7912736 Metges J, Hennequin C, Ychou M et al. (2001) Docetaxel as a second-line chemotherapy in metastatic esophageal cancer: a French study. Proc Am Soc Clin Oncol 20: 160a (Abstract 635) LordickFvon SchillingCBernhardHPhase II trial of irinotecn plus docetaxel in cisplatin-pretreated relapsed or refractory esophageal cancerBr J Cancer20038963063310.1038/sj.bjc.66011681:CAS:528:DC%2BD3sXmtFKqtrw%3D12915869 CoonleyCJBainsMHeelanRPhase II study of etoposide in the treatment of esophageal carcinomaCancer Treat Rep1983673973981:STN:280:DyaL3s3gs1Kktw%3D%3D6850656 PetraschSWeltAReinacherAChemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic esophageal cancerBr J Cancer1998785115141:CAS:528:DyaK1cXlslWjurs%3D9716036 SimonROptimal two-stage designs for phase II clinical trialsControl Clin Trials19891011010.1016/0197-2456(89)90015-91:STN:280:DyaL1M7ps1SjsQ%3D%3D2702835 MauerAHarafDFergusonMDocetaxel-based combined modality therapy for locally advanced carcinoma of the esophagus and gastric cardia (abstract 954)Proc Ann Meet Am Soc Clin Oncol200019246a IlsonDHAjaniJAhallaKPhase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagusJ Clin Oncol199816182618341:CAS:528:DyaK1cXjtFOqsLs%3D9586897 TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Nat Cancer Inst20009220521610.1093/jnci/92.3.2051:STN:280:DC%2BD3c7it1Gitg%3D%3D10655437 LongDLDuffeyPLDeVitaVTJrThe calculation of actual or received dose intensity; a comparison of published methodsJ Clin Oncol1991920422051 WooISJungKHParkYL5-Fluorouracil and cisplatin (FP) combination chemotherapy in advanced esophageal cancerKorean Cancer Assoc199628835841 PoleeMBEskensFAvan der BurgMEPhase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancerBr J Cancer20028666967310.1038/sj.bjc.66001661:CAS:528:DC%2BD38XjtVKjsLk%3D11875723 BleibergHConroyTPaillotBRandomized phases II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell esophageal cancerEur J Cancer1997331216122010.1016/S0959-8049(97)00088-91:CAS:528:DyaK2sXlvVaksb4%3D9301445 LorenzenSDuysterJLerschCCapecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trialBr J Cancer2005922129213310.1038/sj.bjc.66026451:CAS:528:DC%2BD2MXltVygtbs%3D15942631 AjaniJAContribution of chemotherapy in the treatment of carcinoma of the esophagus: results and commentarySemin Oncol1994214744821:STN:280:DyaK2czhslSjug%3D%3D8042045 HeathEJUrbaSMarshallJPhase II trial of docetaxel chemotherapy in patient with incurable adenocarcinoma of the esophagusInvest New Drugs200220959910.1023/A:10144766028041:CAS:528:DC%2BD38Xjt1yltbw%3D12003198 FosellaFVLeeJSMurphyWKPhase II study of docetaxel for recurrent or metastatic non-small cell lung cancerJ Clin Oncol19941212381244 Korean National Cancer Center (2007) Korean central cancer registry 22nd annual report. http://www.ncc.re.kr EinzigALNeubergDRemickSCPhase II trial of docetaxel (taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology group (ECOG) results of protocol E1293Med Oncol199613879310.1007/BF029938581:STN:280:DyaK2s7msFOisg%3D%3D9013471 MuroKHamaguchiTOhtsuAA phase II study of single-agent docetaxel in patients with metastatic esophageal cancerAnn Oncol20041595595910.1093/annonc/mdh2311:STN:280:DC%2BD2c3lt12jtA%3D%3D15151954 AL Einzig (1130_CR7) 1996; 13 CJ Coonley (1130_CR3) 1983; 67 1130_CR12 1130_CR1 P Therasse (1130_CR14) 2000; 92 MB Polee (1130_CR5) 2002; 86 FV Fosella (1130_CR21) 1994; 12 A Jatoi (1130_CR17) 2002; 32 K Muro (1130_CR13) 2004; 15 S Lorenzen (1130_CR23) 2005; 92 F Lordick (1130_CR18) 2003; 89 R Simon (1130_CR15) 1989; 10 DH Ilson (1130_CR20) 1998; 16 EJ Heath (1130_CR8) 2002; 20 H Bleiberg (1130_CR10) 1997; 33 JA Ajani (1130_CR2) 1994; 86 IS Woo (1130_CR9) 1996; 28 DL Long (1130_CR16) 1991; 9 A Sparreboom (1130_CR11) 1998; 9 A Mauer (1130_CR6) 2000; 19 S Petrasch (1130_CR19) 1998; 78 JA Ajani (1130_CR4) 1994; 21 E Laack (1130_CR22) 2005; 28 |
References_xml | – volume: 32 start-page: 115 year: 2002 ident: 1130_CR17 publication-title: Int J Gastrointest Cancer doi: 10.1385/IJGC:32:2-3:115 contributor: fullname: A Jatoi – volume: 21 start-page: 474 year: 1994 ident: 1130_CR4 publication-title: Semin Oncol contributor: fullname: JA Ajani – volume: 92 start-page: 205 year: 2000 ident: 1130_CR14 publication-title: J Nat Cancer Inst doi: 10.1093/jnci/92.3.205 contributor: fullname: P Therasse – volume: 9 start-page: 2042 year: 1991 ident: 1130_CR16 publication-title: J Clin Oncol doi: 10.1200/JCO.1991.9.11.2042 contributor: fullname: DL Long – volume: 20 start-page: 95 year: 2002 ident: 1130_CR8 publication-title: Invest New Drugs doi: 10.1023/A:1014476602804 contributor: fullname: EJ Heath – volume: 28 start-page: 647 year: 2005 ident: 1130_CR22 publication-title: Onkologie doi: 10.1159/000089102 contributor: fullname: E Laack – volume: 28 start-page: 835 year: 1996 ident: 1130_CR9 publication-title: Korean Cancer Assoc contributor: fullname: IS Woo – volume: 33 start-page: 1216 year: 1997 ident: 1130_CR10 publication-title: Eur J Cancer doi: 10.1016/S0959-8049(97)00088-9 contributor: fullname: H Bleiberg – ident: 1130_CR12 – volume: 15 start-page: 955 year: 2004 ident: 1130_CR13 publication-title: Ann Oncol doi: 10.1093/annonc/mdh231 contributor: fullname: K Muro – volume: 16 start-page: 1826 year: 1998 ident: 1130_CR20 publication-title: J Clin Oncol doi: 10.1200/JCO.1998.16.5.1826 contributor: fullname: DH Ilson – volume: 92 start-page: 2129 year: 2005 ident: 1130_CR23 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6602645 contributor: fullname: S Lorenzen – volume: 86 start-page: 669 year: 2002 ident: 1130_CR5 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6600166 contributor: fullname: MB Polee – volume: 12 start-page: 1238 year: 1994 ident: 1130_CR21 publication-title: J Clin Oncol doi: 10.1200/JCO.1994.12.6.1238 contributor: fullname: FV Fosella – volume: 67 start-page: 397 year: 1983 ident: 1130_CR3 publication-title: Cancer Treat Rep contributor: fullname: CJ Coonley – volume: 9 start-page: 1 year: 1998 ident: 1130_CR11 publication-title: Anticancer Drugs doi: 10.1097/00001813-199801000-00001 contributor: fullname: A Sparreboom – volume: 89 start-page: 630 year: 2003 ident: 1130_CR18 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6601168 contributor: fullname: F Lordick – ident: 1130_CR1 – volume: 19 start-page: 246a year: 2000 ident: 1130_CR6 publication-title: Proc Ann Meet Am Soc Clin Oncol contributor: fullname: A Mauer – volume: 13 start-page: 87 year: 1996 ident: 1130_CR7 publication-title: Med Oncol doi: 10.1007/BF02993858 contributor: fullname: AL Einzig – volume: 86 start-page: 1086 year: 1994 ident: 1130_CR2 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/86.14.1086 contributor: fullname: JA Ajani – volume: 10 start-page: 1 year: 1989 ident: 1130_CR15 publication-title: Control Clin Trials doi: 10.1016/0197-2456(89)90015-9 contributor: fullname: R Simon – volume: 78 start-page: 511 year: 1998 ident: 1130_CR19 publication-title: Br J Cancer doi: 10.1038/bjc.1998.524 contributor: fullname: S Petrasch |
SSID | ssj0004133 |
Score | 2.1285045 |
Snippet | Objective The objective of this study was to evaluate the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy in patients with metastatic... Objective The objective of this study was to evaluate the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy in patients with metastatic... The objective of this study was to evaluate the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy in patients with metastatic... Objective: The objective of this study was to evaluate the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy in patients with... |
SourceID | proquest crossref pubmed pascalfrancis springer fao |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 31 |
SubjectTerms | Adolescent Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Cancer Research Cisplatin - administration & dosage Cisplatin - adverse effects Disease-Free Survival Esophageal Neoplasms - drug therapy Esophageal Neoplasms - mortality Esophageal Neoplasms - pathology Esophagus Gastroenterology. Liver. Pancreas. Abdomen Humans Male Medical sciences Medicine Medicine & Public Health Middle Aged Neoplasm Metastasis Neoplasms, Squamous Cell - drug therapy Neoplasms, Squamous Cell - mortality Neoplasms, Squamous Cell - pathology Neutropenia - chemically induced Oncology Original Article Pharmacology. Drug treatments Pharmacology/Toxicology Taxoids - administration & dosage Taxoids - adverse effects Tumors |
SummonAdditionalLinks | – databaseName: SpringerLINK - Czech Republic Consortium dbid: AGYKE link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB61Wwlx4VEeDYVqDqgHqFd52MnmuEItLQhUia5UTtE4sUvVkl02uxLLX-BPM85jo6rl0LMTK7Y_z3zxzHwGeFukpHSkCiGDkIQsTCQoIRdwZa4dF9a5WJdt8TU-nshP5-p8A8L10UV5NewikrWhXte61UFAUav3s90V8SZsKaf3NYCt8cfvnw_7asiguUA-klKoxJddLPOuTm54o01LU5cbSRVPj23utbiLeN4Kmta-6OhxUx9Y1RKGLgXlarhc6GH-57bA4z2G-QQetdQUxw2WnsKGKbfhwZc2-L4N-6eNzPXqAM_6qq3qAPfxtBfAXj2Dv2Os8xSFy_w0c5z9YFeJJydYa9ni1GLBXnNBv801zq6XFfIMzFxOXolUob1kQioc-8WmOGyF3NDqv1boDo7xJ7_tSqEuc6x-LckdX6ALQaBxtzKwieRx5A7P8-cwOTo8-3As2ksfRM5cbiECHceuODeXstA-QyyVzODysFAmMLlfxJqiMCU_t-TEB9NCaaOtinxSMooSil7AoJyWZgdQk9VKW99SznbKEiWGXTHDrzCJJRt58K5b_GzWaHtkaxXneh0yXofMrUMWe7DD8Mjogm1vNvkWuogv_5ulYcJNezcws-6Mqa1SI3_kwW4Hoqw1EVXmpPQk__z6HuC6lfe2my0qDU9clkipUjVKQw9eNtDrvzOtlQQDD953OOq7_u8gXt3r6V142OVK-MFrGCzmS_OGKdhC77V77h_X2Sc0 priority: 102 providerName: Springer Nature |
Title | multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer |
URI | https://link.springer.com/article/10.1007/s00280-009-1130-6 https://www.ncbi.nlm.nih.gov/pubmed/19763571 https://www.proquest.com/docview/213442490 https://search.proquest.com/docview/744595892 |
Volume | 66 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEB6RRkJcEJRHTSGaA-oBusKPXTs-oaRKaEFEETRSOFlre7dUKokbJxL5DfxpZvxIVPG42IeVrfXO7MznnZlvAF7nsVZpoHIhPV8LmZtA6EhzwJWwdphbdrGcbTEJz2fy41zNm9ycskmrbG1iZajzZcZn5O-YeUzSv4L7vrgV3DSKg6tNB40OdH1PcpS2OxxNpl_2hZFe3UueHhUqcmUb1nQrFlG_z0XVsfDIjovwjmPqWL3kNEld0krZusXF3zDoH_HTyi2NH8HDBk_ioFaAx3DPLA7h_ucmYn4IJ9Oam3p7ipf7UqvyFE9wumet3j6BXwOskgsFp2uaFRbfyb_hxQVWBLS4tEhrZNb6p7nB4mZTIs214ES6BeoS7TWhSMGQFeuKri3SQEPaWiKf9uIPeprrl64zLG83ms8ckOMGaLiVAtk1-o6MlXD1FGbj0eXZuWg6NYiMANhaeGkYckVtJmWeuqQXsSTYlfm5Mp7J3DxMdeDH2s2sZsbAOFepSa0KXK1kEEQ6eAYHi-XCHAGm2qYqta7VGRkXq3VkyH-SzuQmstoGDrxpxZQUNSFHsqNermSakEwTlmkSOnBEgkz0FRnMZPbV5zAt_VDFfkRDvTvS3b2M8KhSfbfvwHEr7qTZ12Wy00IHcDdKG5JXSy8MLVwSSali1Y99B57XSrKfZ1zR_3kOvG21Zv_qf37Ei_9O5BgetAkNrvcSDtarjXlFOGmd9qATzSO69s-8HnQH4-FwwvcP3z6Nes1OodGZP_gN4TgVjA |
link.rule.ids | 315,786,790,12083,12250,21416,27955,27956,31752,31753,33299,33300,33777,33778,41114,41556,42183,42625,43343,43612,43838,52144,52267,74100,74369,74657 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZokYALgvJoKJQ5oB6gVvOwk80JVRXVLrRVJXal3qxJYkOlkk03uxL7G_jTzOSxUcXjbCWyPeOZseebb4R4V6Sos0gXUgUhSlXYSGKCnHClWDsuHLtYRltcxOOZ-nylrzpsTt3BKnub2BjqYp7zG_kRM48puiv4H6tbyU2jOLnaddDYEvdVRK6aC8VPBoQH2ee2O7JSUie-6pOafsMhGo64pDqVAVlxGd9xS1sO5wySxJr2ybUNLv4Wgf6RPW2c0ukT8biLJuG4Ff9Tcc-WO-LBeZcv3xEHly0z9foQpkOhVX0IB3A5cFavn4lfx9BACyWDNe0Cqu_k3WAygYZ-FuYOaIfsEn_aG6huVjXQXCuG0ZWANbhriiElB6zQ1nOtgQY6ytYa-K0XftDXXL10nUN9u0J-cQDOGoDlRgpk1WgdOavg4rmYnX6anoxl16dB5hR-LWWQxTHX0-ZKFZlPWpEqCrrysNA2sLlfxBlGYYp-7pD5AtNCZzZzOvJRqyhKMHohtst5aXcFZOgynTnfYU6mxSEmlrwnaUxhE4cu8sT7Xkymauk4zIZ4uZGpIZkalqmJPbFLgjT4jcylmX0NOUlL16k0TGho_450Nz-jaFTrkT_yxF4vbtOd6tpsdNATsBml48i7haWljTOJUjrVozT0xMtWSYZ5pg35X-CJD73WDL_-5yJe_Xcib8XD8fT8zJxNLr7siUc9tMEPXovt5WJl31DEtMz2m3PxG2yZETE |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZokSouCMqjoVDmgHqAWnUSO9mcUAWsujyqlehKe7MmiQ2VSna72ZXY38CfZiaPXVU8zlYs2zOe-eKZ-UaIV2WGJo9NKXUYodSliyWmyAFXwtpJ6dnFcrbFRXI-0R-nZtpRCtVdWmVvExtDXc4KfiM_ZeYxTf8K6tR3WRHj98O38xvJDaQ40Np109gRd8lJKu7ikE7TbYlk2HaVp0mkSZXuA5yq4RONBlxencmQLLpMbrmoHY8zTpjEms7Mt80u_oZG_4ikNg5q-EDc75AlnLWq8FDccdW-2PvSxc73xfG4Zalen8DltuiqPoFjGG_5q9ePxK8zaNIMJSduugXMv5Ong9EIGipamHmg03JL_OmuYX69qoHWOueUugqwBn9FeFIyeIW2tmsNNNDRt9bA777wg77mSqarAuqbFfLrA3AEARw3VSALR_soWB0Xj8Vk-OHy3bnsejbIgqDYUoZ5knBtbaF1mSvSkEwTACui0rjQFapMcoyjDFXhkbkDs9LkLvcmVmh0HKcYPxG71axyBwJy9LnJvfJYkJnxiKkjT0raU7rUo48D8boXk5231Bx2Q8LcyNSSTC3L1CaBOCBBWvxGptNOvkYcsKVfqyxKaejolnQ3kxEyNWagBoE47MVtuxte240-BgI2o3Q1-bSwcnRwNtXaZGaQRYF42irJdp1ZQwQYBuJNrzXbqf-5iWf_XchLsUdXwn4eXXw6FPf6LAcVPhe7y8XKvSDwtMyPmmvxG6NiFZI |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+multi-center+phase+II+study+of+docetaxel+plus+cisplatin+as+first-line+therapy+in+patients+with+metastatic+squamous+cell+esophageal+cancer&rft.jtitle=Cancer+chemotherapy+and+pharmacology&rft.au=Kim%2C+Jin+Young&rft.au=Do%2C+Young+Rok&rft.au=Park%2C+Keon+Uk&rft.au=Kim%2C+Min+Kyung&rft.date=2010-05-01&rft.issn=0344-5704&rft.eissn=1432-0843&rft.volume=66&rft.issue=1&rft.spage=31&rft.epage=36&rft_id=info:doi/10.1007%2Fs00280-009-1130-6&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s00280_009_1130_6 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0344-5704&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0344-5704&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0344-5704&client=summon |